Skip to main
HYPR

Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine (HYPR) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hyperfine is a promising investment with a unique position in the medical device industry due to their innovative Swoop product and potential for international expansion. While risks exist, such as competition and regulatory approvals, the company's strong revenue growth projections and experienced leadership team make it a strong investment opportunity for those with a positive outlook.

Bears say

Hyperfine is currently experiencing a period of lower revenue growth and an increase in cash burn, which suggests that the commercial traction of the Swoop system may not be as strong as initially anticipated. Additionally, the company's reliance on AI software updates to expand clinical utility and deepen their software moat may not be sustainable in the long term, and competition in the MRI market is increasing with new players entering the space. These factors, combined with potential geopolitical risks and lumpiness in quarterly performance due to the small and developing install base, make us skeptical about the sustainability of Hyperfine's growth and profitability in the future.

Hyperfine (HYPR) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hyperfine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hyperfine (HYPR) Forecast

Analysts have given Hyperfine (HYPR) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Hyperfine (HYPR) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.03, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.03, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hyperfine (HYPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.